Apolipoprotein E and alpha-1-antichymotrypsin genotypes do not predict time to psychosis in Alzheimer's disease

Journal of Geriatric Psychiatry and Neurology

Volumn 15, Issue 1, 2002, Pages 24-30

  Sweet, Robert A ^a   Kamboh, M Ilyas ^b   Wisniewski, Stephen R ^c   Lopez, Oscar L ^c   Klunk, William E ^a   Kaufer, Daniel I ^c   DeKosky, Steven T ^d  

^a Division of Geriatrics and Neuropsychiatry   (United States)

^b UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^c Department of Epidemiology ^*  (United States)

^d Section of Comparative Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ANTICHYMOTRYPSIN; APOLIPOPROTEIN E; APOLIPOPROTEIN E4;

ADULT; AGED; ALLELE; ALPHA 1 ANTITRYPSIN DEFICIENCY; ALZHEIMER DISEASE; ARTICLE; DATA ANALYSIS; DETERIORATION; DISEASE MARKER; FEMALE; GENETIC ASSOCIATION; GENETIC RISK; GENOTYPE; HUMAN; HYPERLIPOPROTEINEMIA TYPE 3; MAJOR CLINICAL STUDY; MALE; NONBIOLOGICAL MODEL; ONSET AGE; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; PSYCHOSIS; SURVIVAL; SYMPTOMATOLOGY;

AGE OF ONSET; AGED; ALPHA 1-ANTICHYMOTRYPSIN; ALZHEIMER DISEASE; APOLIPOPROTEIN E4; APOLIPOPROTEINS E; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; LONGITUDINAL STUDIES; MALE; PROGNOSIS; PSYCHOTIC DISORDERS; RISK FACTORS;

EID: 0036128456     PISSN: 08919887     EISSN: None     Source Type: Journal    
DOI: 10.1177/089198870201500106     Document Type: Article

References (56)

1. Overview of depression and psychosis in Alzheimer's disease
2. Noncognitive disturbances in Alzheimer's disease: Frequency, longitudinal course, and relationship to cognitive symptoms
3. Longitudinal assessment of symptoms of depression, agitation, and psychosis in 181 patients with Alzheimer's disease
4. Psychiatric medication and abnormal behavior as predictors of progression in probable Alzheimer disease
5. The course of psychopathologic features in mild to moderate Alzheimer disease
6. Mental and behavioral disturbances in dementia: Findings from the Cache County study on memory in aging
7. Incidence of and risk factors for hallucinations and delusions in patients with probable Alzheimer's disease
8. Predictors of disease course in patients with probable Alzheimer's disease
9. Cognitive deficits of patients with Alzheimer's disease with and without delusions
10. Predictors of cognitive and functional progression in patients with probable Alzheimer's disease
11. Risk of mortality and institutionalization in demented patients with delusions
12. Psychotic symptoms in dementia and the rate of cognitive decline
13. Do neuroleptic drugs hasten cognitive decline in dementia? Prospective study with necropsy follow up
14. Dopamine receptor genetic variation, psychosis, and aggression in Alzheimer's disease
15. 5-HT2A and 5-HT2C receptor polymorphisms and psychopathology in late onset Alzheimer's disease
16. Hallucinations and associated factors in Alzheimer's disease
17. Clinical variables associated with psychosis in Alzheimer's disease
18. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families
19. Accelerated decline in apolipoprotein E-epsilon4 homozygotes with Alzheimer's disease
20. Apolipoprotein Ee4, other risk factors, and course of Alzheimer's disease
21. Apolipoprotein-E (APO-E) genotype and symptoms of psychosis in Alzheimer's disease
22. A preliminary study of apolipoprotein E genotype and psychiatric manifestations of Alzheimer's disease
23. Apohpoprotein E: Non-cognitive symptoms and cognitive decline in late onset Alzheimer's disease
24. The apolipoprotein E e4 allele is not associated with psychiatric symptoms or extrapyramidal signs in probable Alzheimer's disease
25. Factors associated with psychotic symptoms in Alzheimer's disease
26. Behavioral changes associated with different apolipoprotein E genotypes in dementia
27. Psychotic symptoms and apolipoprotein E genotypes in an elderly population
28. Apolipoprotein E genotype and noncognitive symptoms in Alzheimer's disease
29. Clinical and neuropsychological characteristics in familial and sporadic Alzheimer's disease: Relation to apolipoprotein E polymorphism
30. Depression, delusions, and hallucinations in Alzheimer's disease: No relationship to apolipoprotein E genotype
31. APOE*4-associated Alzheimer's disease risk is modified by α1-antichymotrypsin polymorphism
32. 1-Antichymotrypsin as a risk modifier for late-onset Alzheimer's disease in Japanese apolipoprotein E e4 allele carriers
33. 1-antichymotrypsin polymorphism in Alzheimer's disease
34. 1-Antichymotrypsin gene polymorphism and risk for Alzheimer's disease
35. α-Antichymotrypsin gene polymorphism and risk for Alzheimer's disease in the Spanish population
36. No association between the alpha 1-antichymotrypsin A allele and Alzheimer's disease
37. No interaction between the APOE and the alpha-1-antichymotrypsin genes on risk for Alzheimer's disease
38. 1-antichymotrypsin in Alzheimer disease
39. The natural history of Alzheimer's disease: Description of study cohort and accuracy of diagnosis
40. Psychotic symptoms in Alzheimer's disease are not associated with more severe neuropathologic features
41. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease
42. The behavior rating scale for dementia of the consortium to establish a registry for Alzheimer's disease
43. Alterations of striatal dopamine receptor binding in Alzheimer's disease are associated with Lewy body pathology and with antemortem psychosis
44. Neuropathologic and neurochemical correlates of psychosis in primary dementia
45. Neuropathological correlates of psychotic phenomena in confirmed Alzheimer's disease
46. Biochemical, neuropathological, and clinical correlations of neurofibrillary degeneration in Alzheimer's disease
47. Increased neocortical neurofibrillary tangle density in subjects with Alzheimer's disease
48. Lewy bodies in Alzheimer's disease: A neuropathological review of 145 cases using α-synuclein immunohistochemistry
49. Alzheimer's disease and its Lewy body variant: A clinical analysis of postmortem verified cases
50. Operational criteria for senile dementia of Lewy body type (SDLT)
51. The Lewy body variant of Alzheimer's disease: A clinical and pathologic entity
52. Severity of cognitive impairment and the clinical diagnosis of AD with Lewy bodies
53. Chromosome 17 and hereditary dementia: Linkage studies in three non-Alzheimer families and kindreds with late-onset FAD
54. A meta-analysis and transmission disequilibrium study of association between the dopamine D3 receptor gene and schizophrenia
55. 3 receptors and use of antipsychotics in patients with schizophrenia: A postmortem study